Overview

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as a component of TAS-102 with FTD alone.
Phase:
Phase 1
Details
Lead Sponsor:
Taiho Oncology, Inc.
Treatments:
Trifluridine